Cellosaurus PANC-1 (CVCL_0480)

Cell line name PANC-1
Synonyms Panc-1; PANC.1; Panc 1; PanC1; Panc1; PANC1
Accession CVCL_0480
Resource Identification Initiative To cite this cell line use: PANC-1 (RRID:CVCL_0480)
Comments Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: ENCODE project common cell types; tier 3.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Characteristics: Has lost chromosome Y.
Doubling time: ~42 hours (DSMZ).
Sequence variation: Homozygous for a CDKN2A deletion (PubMed=11787853).
Sequence variation: Heterozygous for KRAS p.Gly12Asp (PubMed=7809022; PubMed=8026879; PubMed=11787853).
Sequence variation: TP53 p.Arg273His (PubMed=8026879; PubMed=11787853).
Omics: Array-based CGH.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_1778 (1.1B4); CVCL_2257 (1.1E7); CVCL_2259 (1.4E7); CVCL_3002 (KP-1N); CVCL_0Q68 (Panc1-MUC1)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; DSMZ; ECACC; KCLB; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX
CSF1PO10,12
D13S31711
D16S53911
D18S5112
D21S1128
D3S135817
D5S81811,13
D7S8208,10
D8S117914,15
FGA21
Penta D14
Penta E7,14
TH017,8
TPOX8,11
vWA15
Web pages http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/PANC-1.html
http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=PANC-1
http://genome.ucsc.edu/ENCODE/protocols/cell/human/PANC-1_Myers_protocol.pdf
https://strap.nci.nih.gov/celline_detail.php?sample_id=65
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-179.html
http://tcpaportal.org/mclp/
http://www.phe-culturecollections.org.uk/media/120309/panc-1-cell-line-profile.pdf
Publications

PubMed=1140870; DOI=10.1002/ijc.2910150505
Lieber M.M., Mazzetta J., Nelson-Rees W.A., Kaplan M., Todaro G.J.
Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas.
Int. J. Cancer 15:741-747(1975)

PubMed=6435863
Chang B.K., Black O. Jr., Gutman R.
Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Cancer Res. 44:5100-5104(1984)

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8286197; DOI=10.1038/bjc.1994.24
Lohr M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.
Br. J. Cancer 69:144-151(1994)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)

PubMed=15688027; DOI=10.1038/sj.onc.1208383
Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Oncogene 24:1794-1801(2005)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

DOI=10.4172/jpb.1000057
Masayo Y., Kiyonaga F., Koji K., Setsuo H., Tadashi K.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinform. 2:1-18(2009)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections AddexBio; C0018010/4923
ATCC; CRL-1469
BCRC; 60284
BCRJ; 0201
CLS; 300228/p635_Panc-1
DSMZ; ACC-783
ECACC; 87092802
IZSLER; BS TCL 49
KCB; KCB 200809YJ
KCLB; 21469
NCBI_Iran; C556
RCB; RCB2095
TKG; TKG 0606
Cell line databases/resources CLDB; cl3872
CLDB; cl3873
CLDB; cl3874
CCLE; PANC1_PANCREAS
CCRID; 3111C0001CCC000023
CCRID; 3131C0001000700098
CGH-DB; 180-1
CGH-DB; 9267-4
LINCS_LDP; LCL-1726
SKY/M-FISH/CGH; 2001
TOKU-E; 2865
Ontologies BCGO; BCGO_0000122
BTO; BTO:0000304
CLO; CLO_0008381
CLO; CLO_0050102
EFO; EFO_0002713
MCCL; MCC:0000378
Biological sample resources BioSample; SAMN01821587
BioSample; SAMN03472068
ENCODE; ENCBS397PLZ
ENCODE; ENCBS399ENC
ENCODE; ENCBS425ENC
ENCODE; ENCBS465AAA
ENCODE; ENCBS466AAA
ENCODE; ENCBS467AAA
ENCODE; ENCBS470AAA
ENCODE; ENCBS492WPY
ENCODE; ENCBS556WYR
ENCODE; ENCBS761TKL
ENCODE; ENCBS729QZR
ENCODE; ENCBS945URM
Chemistry resources ChEMBL-Cells; CHEMBL3307545
ChEMBL-Targets; CHEMBL614139
Gene expression databases GEO; GSM206532
GEO; GSM244423
GEO; GSM472938
GEO; GSM472939
GEO; GSM621900
GEO; GSM784698
GEO; GSM887501
GEO; GSM888583
GEO; GSM923421
GEO; GSM945246
GEO; GSM945261
GEO; GSM1024411
GEO; GSM1374806
GEO; GSM1374807
GEO; GSM1374808
GEO; GSM1435699
GEO; GSM1435700
GEO; GSM1435701
GEO; GSM1588613
Polymorphism and mutation databases Cosmic; 707250
Cosmic; 710864
Cosmic; 724643
Cosmic; 730533
Cosmic; 753625
Cosmic; 808171
Cosmic; 868242
Cosmic; 873000
Cosmic; 913307
Cosmic; 918054
Cosmic; 922248
Cosmic; 923171
Cosmic; 932521
Cosmic; 947397
Cosmic; 948377
Cosmic; 949235
Cosmic; 968106
Cosmic; 1006367
Cosmic; 1108335
Cosmic; 1122348
Cosmic; 1198204
Cosmic; 1299304
Cosmic; 1320459
Cosmic; 1366282
Cosmic; 1477432
Cosmic; 1518236
Cosmic; 1534320
Cosmic; 1571781
Cosmic; 1644316
Cosmic; 1609544
Cosmic; 1768264
Cosmic; 2434107
Cosmic; 2546060
Proteomic databases PRIDE; PXD002192
PRIDE; PXD003198